Is there a role for assessing measurable/minimal residual disease (MRD) in multiple myeloma at this time?

MRD assessment in myeloma is challenging. The EuroFlow standard and Adaptive ClonoSEQ technologies seem to be winning out for the moment, but the Mayo Clinic mass spectrometry peripheral blood assay may be the next generation. The advantage of the flow-cytometry based assay is that it involves live ...